Precigen: Why I Am More Cautious After The Q1 Beat (Downgrade)
Precigen, Inc. reported $21.6 million in Q1 revenue from Papzimeos, meeting expectations but lacking key launch metrics. The company's management anticipates reaching cash flow breakeven by the end of the year, although concerns about cash burn and margin compression persist. Due to these factors, the stock rating has been downgraded to Hold as the risk-reward profile has diminished.
- ▪Precigen, Inc. achieved $21.6 million in Q1 revenue from Papzimeos.
- ▪The company did not disclose key launch metrics, raising concerns about future performance.
- ▪Management expects to reach cash flow breakeven by year-end, but risks related to cash burn and margins remain.
Opening excerpt (first ~120 words) tap to expand
{"@context":"https://schema.org","@type":"BreadcrumbList","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https://seekingalpha.com/"},{"@type":"ListItem","position":2,"name":"Earnings Analysis","item":"https://seekingalpha.com/earnings/earnings-analysis"},{"@type":"ListItem","position":3,"name":"Healthcare ","item":"https://seekingalpha.com/stock-ideas/healthcare"}]}{"@context":"https://schema.org","@type":"NewsArticle","mainEntityOfPage":{"@type":"WebPage","@id":"https://seekingalpha.com/article/4907695-precigen-why-i-am-more-cautious-after-the-q1-beat-downgrade"},"author":{"@type":"Person","name":"Stephen…
Excerpt limited to ~120 words for fair-use compliance. The full article is at Seeking Alpha.
Discussion
0 commentsMore from Seeking Alpha
